https://www.selleckchem.com/pr....oducts/enfortumab-ve
At Week 145 (n=160; dose 39.4±0.83mg/day), mean change from baseline in AIMS score was -6.6±0.37; 73% of patients experienced treatment success. Treatment was generally well tolerated across 723 patient-years of exposure through Week 158, and exposure-adjusted incidence rates (incidence/patient-years) for akathisia/restlessness were 0.01, somnolence/sedation were 0.07, and symptoms which may represent parkinsonism or depression were 0.08 each. Patients who received long-term treatment with deutetrabenazine achieved susta
Curtir
Comentario
Compartilhar
